733 related articles for article (PubMed ID: 26297802)
1. CTLA4-Ig suppresses development of experimental autoimmune uveitis in the induction and effector phases: Comparison with blockade of interleukin-6.
Iwahashi C; Fujimoto M; Nomura S; Serada S; Nakai K; Ohguro N; Nishida K; Naka T
Exp Eye Res; 2015 Nov; 140():53-64. PubMed ID: 26297802
[TBL] [Abstract][Full Text] [Related]
2. Blockade of interleukin-6 signaling suppresses experimental autoimmune uveoretinitis by the inhibition of inflammatory Th17 responses.
Hohki S; Ohguro N; Haruta H; Nakai K; Terabe F; Serada S; Fujimoto M; Nomura S; Kawahata H; Kishimoto T; Naka T
Exp Eye Res; 2010 Aug; 91(2):162-70. PubMed ID: 20420831
[TBL] [Abstract][Full Text] [Related]
3. Blockade of interleukin-6 signaling suppresses not only th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis.
Haruta H; Ohguro N; Fujimoto M; Hohki S; Terabe F; Serada S; Nomura S; Nishida K; Kishimoto T; Naka T
Invest Ophthalmol Vis Sci; 2011 May; 52(6):3264-71. PubMed ID: 21330657
[TBL] [Abstract][Full Text] [Related]
4. [Effects of leflunomide on experimental autoimmune uveitis in Lewis rats].
Fang C; Zhou D; Zhan S; He Y; Lin Z; Huang C; Li J
Zhonghua Yan Ke Za Zhi; 2015 Oct; 51(10):754-61. PubMed ID: 26693771
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
[TBL] [Abstract][Full Text] [Related]
6. Contribution of CD4+CD25+ T cells to the regression phase of experimental autoimmune uveoretinitis.
Sun M; Yang P; Du L; Zhou H; Ren X; Kijlstra A
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):383-9. PubMed ID: 19696173
[TBL] [Abstract][Full Text] [Related]
7. Oral administration of retinoic acid receptor-alpha/beta-specific ligand Am80 suppresses experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Okada AA
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1548-56. PubMed ID: 20861477
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic effect of the potent IL-12/IL-23 inhibitor STA-5326 on experimental autoimmune uveoretinitis.
Keino H; Watanabe T; Sato Y; Niikura M; Wada Y; Okada AA
Arthritis Res Ther; 2008; 10(5):R122. PubMed ID: 18847496
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of DR3 expression in CD4⁺ T cells promotes secretion of IL-17 in experimental autoimmune uveitis.
Qin T
Mol Vis; 2011; 17():3486-93. PubMed ID: 22219644
[TBL] [Abstract][Full Text] [Related]
10. SLAT/Def6 plays a critical role in the pathogenic process of experimental autoimmune uveitis (EAU).
Vistica BP; Shi G; Nugent L; Tan C; Altman A; Gery I
Mol Vis; 2012; 18():1858-64. PubMed ID: 22815639
[TBL] [Abstract][Full Text] [Related]
11. S-nitrosoglutathione prevents interphotoreceptor retinoid-binding protein (IRBP(161-180))-induced experimental autoimmune uveitis.
Haq E; Rohrer B; Nath N; Crosson CE; Singh I
J Ocul Pharmacol Ther; 2007 Jun; 23(3):221-31. PubMed ID: 17593005
[TBL] [Abstract][Full Text] [Related]
12. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response.
Jones LS; Rizzo LV; Agarwal RK; Tarrant TK; Chan CC; Wiggert B; Caspi RR
J Immunol; 1997 Jun; 158(12):5997-6005. PubMed ID: 9190954
[TBL] [Abstract][Full Text] [Related]
13. [Effects of exogenous interleukin-2, interleukin-23 on differentiation of IRBP 1-20-specific T cells toward Th1 and Th17 and comparison of the pathogenicity of IRBP 1-20-specific T cells].
Li Y; Cui Y; Bi HS; Wang Y; Li J; Wang XR
Zhonghua Yan Ke Za Zhi; 2013 Mar; 49(3):224-9. PubMed ID: 23866703
[TBL] [Abstract][Full Text] [Related]
14. Crucial role of P2X
Takeda A; Yamada H; Hasegawa E; Arima M; Notomi S; Myojin S; Yoshimura T; Hisatomi T; Enaida H; Yanai R; Kimura K; Ishibashi T; Sonoda KH
Jpn J Ophthalmol; 2018 May; 62(3):398-406. PubMed ID: 29572578
[TBL] [Abstract][Full Text] [Related]
15. Endogenous IL-12 is required for induction and expression of experimental autoimmune uveitis.
Tarrant TK; Silver PB; Chan CC; Wiggert B; Caspi RR
J Immunol; 1998 Jul; 161(1):122-7. PubMed ID: 9647215
[TBL] [Abstract][Full Text] [Related]
16. Characterization of IL-17+ interphotoreceptor retinoid-binding protein-specific T cells in experimental autoimmune uveitis.
Peng Y; Han G; Shao H; Wang Y; Kaplan HJ; Sun D
Invest Ophthalmol Vis Sci; 2007 Sep; 48(9):4153-61. PubMed ID: 17724201
[TBL] [Abstract][Full Text] [Related]
17. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide.
Keino H; Kezuka T; Takeuchi M; Yamakawa N; Hattori T; Usui M
Arch Ophthalmol; 2004 Aug; 122(8):1179-84. PubMed ID: 15302659
[TBL] [Abstract][Full Text] [Related]
18. Differentiation of Th1 and Th2 cells in lymph nodes and spleens of mice during experimental autoimmune uveoretinitis.
Takeuchi M; Yokoi H; Tsukahara R; Sakai J; Usui M
Jpn J Ophthalmol; 2001; 45(5):463-9. PubMed ID: 11583666
[TBL] [Abstract][Full Text] [Related]
19. Suppression of established experimental autoimmune uveitis by anti-LFA-1alpha Ab.
Ke Y; Sun D; Zhang P; Jiang G; Kaplan HJ; Shao H
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2667-75. PubMed ID: 17525198
[TBL] [Abstract][Full Text] [Related]
20. Suppression of experimental autoimmune uveitis by angiotensin II type 1 receptor blocker telmisartan.
Okunuki Y; Usui Y; Nagai N; Kezuka T; Ishida S; Takeuchi M; Goto H
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2255-61. PubMed ID: 19136706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
